ATE312612T1 - Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen - Google Patents
Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungenInfo
- Publication number
- ATE312612T1 ATE312612T1 AT99969336T AT99969336T ATE312612T1 AT E312612 T1 ATE312612 T1 AT E312612T1 AT 99969336 T AT99969336 T AT 99969336T AT 99969336 T AT99969336 T AT 99969336T AT E312612 T1 ATE312612 T1 AT E312612T1
- Authority
- AT
- Austria
- Prior art keywords
- immune
- mercaptopurine
- optimizing
- mediated gastrointestinal
- treatment
- Prior art date
Links
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 title abstract 5
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 3
- 229960001428 mercaptopurine Drugs 0.000 title abstract 2
- 208000010643 digestive system disease Diseases 0.000 abstract 2
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10171498P | 1998-09-24 | 1998-09-24 | |
| US09/288,344 US6355623B2 (en) | 1998-09-24 | 1999-04-08 | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| PCT/IB1999/001691 WO2000016780A1 (en) | 1998-09-24 | 1999-09-24 | Optimized use of 6-mercaptopurine drug in the treatment of immune-mediated gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE312612T1 true ATE312612T1 (de) | 2005-12-15 |
Family
ID=26798551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99969336T ATE312612T1 (de) | 1998-09-24 | 1999-09-24 | Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1115403B1 (de) |
| AT (1) | ATE312612T1 (de) |
| AU (1) | AU5994699A (de) |
| CA (1) | CA2345100C (de) |
| DE (1) | DE69928950T2 (de) |
| HK (1) | HK1039563B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117398401B (zh) * | 2021-01-31 | 2025-10-10 | 兰州大学 | 齐多夫定在制备预防和/或治疗酒精性胃溃疡药物中的应用 |
-
1999
- 1999-09-24 AT AT99969336T patent/ATE312612T1/de not_active IP Right Cessation
- 1999-09-24 AU AU59946/99A patent/AU5994699A/en not_active Abandoned
- 1999-09-24 HK HK02100245.1A patent/HK1039563B/en not_active IP Right Cessation
- 1999-09-24 DE DE69928950T patent/DE69928950T2/de not_active Expired - Lifetime
- 1999-09-24 EP EP99969336A patent/EP1115403B1/de not_active Expired - Lifetime
- 1999-09-24 CA CA002345100A patent/CA2345100C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5994699A (en) | 2000-04-10 |
| CA2345100C (en) | 2009-05-26 |
| CA2345100A1 (en) | 2000-03-30 |
| HK1039563B (en) | 2006-06-09 |
| EP1115403B1 (de) | 2005-12-14 |
| EP1115403A1 (de) | 2001-07-18 |
| DE69928950T2 (de) | 2006-08-24 |
| HK1039563A1 (en) | 2002-05-03 |
| DE69928950D1 (de) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124763T1 (el) | Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας | |
| HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
| ATE365165T1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| ATE508114T1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| DK1509230T3 (da) | Gefitinib ( IRESSA) til behandlingen af cancer | |
| DK1397681T3 (da) | Fremgangsmåde til identificering af midler til behandling af diabetes | |
| ATE460166T1 (de) | Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| NO20064896L (no) | Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer | |
| ATE312612T1 (de) | Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen | |
| DE60112768D1 (de) | Behandlung von entzündlichen erkrankungen | |
| ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
| PT1133295E (pt) | Utilizacao da nicergolina no tratamento da espasticidade | |
| ATE546548T1 (de) | Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten | |
| EA200501052A1 (ru) | Способ лечения поведенческих расстройств | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| ATE341323T1 (de) | Verwendung von darifenacin zur behandlung des harndrangs | |
| ATE246922T1 (de) | Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen | |
| ATE262343T1 (de) | Verwendung von gnrh analogen zur behandlung von schizophrenie | |
| ATE380884T1 (de) | Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |